Lanean...
The HDAC Inhibitors Scriptaid and LBH589 Combined with the Oncolytic Virus Delta24-RGD Exert Enhanced Anti-Tumor Efficacy in Patient-Derived Glioblastoma Cells
BACKGROUND: A phase I/II trial for glioblastoma with the oncolytic adenovirus Delta24-RGD was recently completed. Delta24-RGD conditionally replicates in cells with a disrupted retinoblastoma-pathway and enters cells via αvβ3/5 integrins. Glioblastomas are differentially sensitive to Delta24-RGD. HD...
Gorde:
Argitaratua izan da: | PLoS One |
---|---|
Egile Nagusiak: | , , , , , , , , |
Formatua: | Artigo |
Hizkuntza: | Inglês |
Argitaratua: |
Public Library of Science
2015
|
Gaiak: | |
Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4436250/ https://ncbi.nlm.nih.gov/pubmed/25993039 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0127058 |
Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|